NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

聚合酵素鏈鎖反應 (PCR) 市場 - 成長,趨勢,及預測(2019年 - 2024年)

Polymerase Chain Reaction Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 871438
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
聚合酵素鏈鎖反應 (PCR) 市場 - 成長,趨勢,及預測(2019年 - 2024年) Polymerase Chain Reaction Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年03月01日內容資訊: 英文 120 Pages
簡介

聚合酵素鏈鎖反應 (PCR)市場成長的主要原因,是臨床診斷中用途的擴大,個體化i醫療及精密醫療的需求高漲,以及醫藥品開發的技術進步及用途。

本報告提供聚合酵素鏈鎖反應市場的相關調查,市場概況和成長要素、阻礙因素,各產品、用途、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 臨床診斷的用途的擴大
    • 個人化醫療及精密醫療的需求高漲
    • 醫藥品開發中技術的進步與應用
  • 市場阻礙因素
    • 設備的高成本
    • 替代技術的出現
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業的競爭

第5章 市場區隔

  • 各產品
    • 設備
    • 試劑及消耗品
    • 軟體
  • 各用途
    • 臨床診斷
    • 生命科學研究和產業用途
    • 其他的用途
  • 各終端用戶
    • 學術機構
    • 臨床診斷檢驗室及醫院
    • 製藥及生物科技產業
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • GE Healthcare
    • Merck KGaA
    • PerkinElmer Inc.
    • Promega Corporation
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc.

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64490

The polymerase chain reaction market is projected to register a CAGR of 8.30% during the forecast period, with a revenue of approximately USD 5,970 million in 2020 and expected to reach USD 10,310 million by 2026. The major factors driving the growth of the polymerase chain reaction market include the increasing application in clinical diagnostics, rising demand for personalized and precision medicine, and technological advancements and application in drug development.

There is a positive impact on the PCR market due to the increasing demand for the clinical diagnostic segment of the market. As the authorities have not recommended the viral culture tests, almost all the diagnostic tests use RT-PCR to test the population who have symptoms of COVID-19 and are advised by healthcare professionals to undergo a diagnostic test.

Furthermore, the polymerase chain reaction is also gaining higher importance in the molecular diagnosis of infectious and genetic diseases with the advent of COVID-19. To facilitate personalized medicine, it is crucial to develop precise and reproducible means of gaining molecular information about the underlying disease, which can be used to guide clinical decision making, with PCR techniques being increasingly utilized in such methods. Therefore, increasing the focus on personalized medicine and patient-centered approach is driving the growth of the market studied.

Personalized medicine, which aims to provide tailor-made therapies to individual patients, depending on the molecular basis of disease, became popular over recent years. The aging global population and the rising prevalence of chronic disease are putting unrelenting pressure on the healthcare system's capacity and financial viability across the world.

According to the World Population Prospects: the 2019 Revision, one in every six people will be over 65 years of age by 2050. The rising demand for personalized medicine has thus created tremendous opportunities in the field of genetic medicine. To gain a competitive advantage in the emerging field of personalized medicine, biotechnology and pharmaceutical firms are exploring the grounds of genomic medicine and direct-to-consumer genetic testing. To develop these products, the industry is ramping up the R&D process in the areas of biotechnology, where the polymerase chain reaction finds its major applications.

Personalized medicine thus holds the promise of providing better patient care and a high safety margin while also lowering the total healthcare costs. Therefore, the increasing geriatric population, demand for personalized medicine, and the role PCR play in developing them boost the market growth.

Key Market Trends

Clinical Diagnostics Segment is Expected to Witness a Good Growth over the Forecast Period

PCR-based molecular diagnostic tests are increasingly being used to guide patient management, particularly in the fields of infectious disease, cancer, and congenital abnormalities. Globally, the prevalence of genetic, infectious, and chronic diseases, coupled with the increased availability of genetic and genomic information, is on the rise and it has led to the rapid incorporation of PCR techniques in clinical laboratories.

As the COVID-19 cases are on the rise and spread of the disease in major countries has increased the demand for the diagnostic test of the virus in the suspected population. This trend is primarily due to the low or non-availability of rapid or specific diagnostic tests for such diseases. Therefore pertaining to broad applications of PCR in clinical diagnostics, the segment is likely to register a high growth during the forecast period.

The high specificity, sensitivity, and low sample requirement make PCR-based molecular assay a go-to technique for the purpose of clinical diagnosis. PCR-based molecular assays are becoming the primary mode of diagnosis for the detection of pathogens in case of a rapid disease outbreak, such as the recent Zika and Coronavirus outbreaks.

North America is Expected to Dominate the Polymerase Chain Reaction Market over the Forecast Period

The increasing prevalence of genetic and chronic disorders, such as cancer, the aging population, the rising demand for precision and personalized medicine, and favorable government initiatives, are the primary factors driving the growth of the market.

As the COVID-19 cases are increasing rapidly and the spread of the virus is very rapid, speeding up the transmission. The increasing count of suspects increases the number of diagnostic tests, boosting the market growth in the country.

Pixel by LabCorp COVID-19 is a test home collection kit where the patient can self-collect nasal swab specimens at home when approved by a healthcare provider to be appropriate based on the results of a COVID-19 questionnaire. The specimen is collected carefully and sent back to the lab for RT-PCR, where the results are produced and sent back. Due to such advancements in the country, it has a cutting edge over the others in the market.

In February 2020, the Department of Health and Human Services has also announced the authorization of the emergency use of diagnostics for the detection of COVID-19. This authorization has increased the number of diagnostics product launches in the region.

There is also a growing trend of genetic engineering and genomic research in academia and biotechnology industries of the United States. Increasing genomic research is primarily fueled by the high demand for targeted and precision medicine, for the management of chronic disorders, as well as due to the need for understanding the genetic and molecular basis of disease. In recent years, several government initiatives were launched, which are supplementing the growth of the PCR market.

Competitive Landscape

The market studied is moderately consolidated in nature, owing to the presence of a few major players. Some of the market players are Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., GE Healthcare, Merck KGaA, PerkinElmer Inc., Promega Corporation, Siemens Healthcare, and Thermo Fisher Scientific Inc. These major companies are found focussing on R&D to develop advanced technology products to gain a competitive edge. Companies are also found engaging in partnerships, mergers, and acquisitions, aiming to strengthen their product portfolio, manufacturing capacities, and provide competitive differentiation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Application in Clinical Diagnostics
    • 4.2.2 Rising Demand for Personalized and Precision Medicine
    • 4.2.3 Technological Advancements and Application in Drug Development
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
    • 4.3.2 Emergence of Alternative Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Instruments
      • 5.1.1.1 Standard PCR Systems
      • 5.1.1.2 Digital PCR Systems
      • 5.1.1.3 Real-time PCR Systems
    • 5.1.2 Reagents and Consumables
    • 5.1.3 Software
  • 5.2 By Application
    • 5.2.1 Clinical Diagnostics
    • 5.2.2 Life Science Research and Industrial Applications
    • 5.2.3 Other Applications
  • 5.3 By End User
    • 5.3.1 Academic Institutes
    • 5.3.2 Clinical Diagnostics Labs and Hospitals
    • 5.3.3 Pharmaceutical and Biotechnology Industries
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (By Product, By Application, and By End User)
      • 5.4.1.2 Canada (By Product, By Application, and By End User)
      • 5.4.1.3 Mexico (By Product, By Application, and By End User)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (By Product, By Application, and By End User)
      • 5.4.2.2 United Kingdom (By Product, By Application, and By End User)
      • 5.4.2.3 France (By Product, By Application, and By End User)
      • 5.4.2.4 Italy (By Product, By Application, and By End User)
      • 5.4.2.5 Spain (By Product, By Application, and By End User)
      • 5.4.2.6 Rest of Europe (By Product, By Application, and By End User)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (By Product, By Application, and By End User)
      • 5.4.3.2 Japan (By Product, By Application, and By End User)
      • 5.4.3.3 India (By Product, By Application, and By End User)
      • 5.4.3.4 Australia (By Product, By Application, and By End User)
      • 5.4.3.5 South Korea (By Product, By Application, and By End User)
      • 5.4.3.6 Rest of Asia-Pacific (By Product, By Application, and By End User)
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC (By Product, By Application, and By End User)
      • 5.4.4.2 South Africa (By Product, By Application, and By End User)
      • 5.4.4.3 Rest of Middle East and Africa (By Product, By Application, and By End User)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (By Product, By Application, and By End User)
      • 5.4.5.2 Argentina (By Product, By Application, and By End User)
      • 5.4.5.3 Rest of South America (By Product, By Application, and By End User)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 bioMerieux SA
    • 6.1.5 Bio-Rad Laboratories Inc.
    • 6.1.6 GE Healthcare
    • 6.1.7 Merck KGaA
    • 6.1.8 PerkinElmer Inc.
    • 6.1.9 Promega Corporation
    • 6.1.10 Siemens Healthcare
    • 6.1.11 Thermo Fisher Scientific Inc.
    • 6.1.12 QIAGEN
    • 6.1.13 F. Hoffmann-La Roche Ltd.
    • 6.1.14 Fluidigm Corporation
    • 6.1.15 Takara Bio Inc.
    • 6.1.16 Danaher Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS